Women Face Higher GLP-1 Side Effect Risks in Diabetes and Obesity Treatment

Limited sex-specific clinical trial data leaves doctors balancing benefits and side effects for female patients

Emerging analyses show that women using GLP-1 receptor agonists such as semaglutide, liraglutide, and tirzepatide report more adverse events than men, including neurologic and psychiatric symptoms. These differences may stem from higher drug concentrations in women, yet sex-specific data remain scarce in clinical trials.

Study Details:

GLP-1 receptor agon…